CG Oncology, Inc. Other Noncash Income
CG Oncology, Inc. (CGON) reported Other Noncash Income of $768.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncome · last filed 2026-02-27
- CG Oncology, Inc. other noncash income for the quarter ending 2025-12-31 was -$76.00K.
- CG Oncology, Inc. other noncash income for the quarter ending 2025-09-30 was $169.00K.
- CG Oncology, Inc. other noncash income for the quarter ending 2025-06-30 was $499.00K.
- CG Oncology, Inc. other noncash income for the quarter ending 2025-03-31 was $176.00K.
- CG Oncology, Inc. other noncash income for fiscal 2025 was $768.00K.
| Period end | Other Noncash Income 3 month | Other Noncash Income 6 month | Other Noncash Income 9 month | Other Noncash Income 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $93.00K derived: sum of 2 quarters · filed 2026-02-27 | $592.00K derived: sum of 3 quarters · filed 2026-02-27 | $768.00K 10-K · filed 2026-02-27 |
| 2025-09-30 | $169.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $668.00K derived: sum of 2 quarters · filed 2025-11-14 | $844.00K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $499.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $675.00K 10-Q · filed 2025-08-08 | ||
| 2025-03-31 | $176.00K 10-Q · filed 2025-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |